Infectious Diseases

Merck has collaborated with the Seattle-based Institute for Systems Biology (ISB) to further study novel coronavirus SARS-CoV-2. The primary goal of the collaboration will be to investigate the molecular pathway of SARS-CoV-2 and aetiology of COVID-19 with the intent of finding an effective and standard treatment for the disease. Merck will facilitate the funding, whereas, ISB will be accelerating the research, targeting drugs and molecules, evaluating changes in immune systems post-SARS-CoV-2 evaluating changes in immune systems post-SARS-CoV-2 infection and characterizing neutralizing antibodies in convalescent patients. Merck’s deal with BARDA will al...